This page shows the latest Incivek news and features for those working in and with pharma, biotech and healthcare.
The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.
It can also be used in patients with advanced liver disease and who have failed prior treatment with HCV protease inhibitors such as Merck &Co's Victrelis (boceprevir) and Vertex' Incivek
and Vertex' Incivek (telaprevir).
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some
More from news
Approximately 0 fully matching, plus 24 partially matching documents found.
a decade of trial and error, the company had a huge breakthrough drug on its hands: hepatitis C treatment Incivek. ... Launched in 2011, Incivek enjoyed the most successful launch in pharma history, earning $1.6bn in sales during its first 12 months on.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...